Impact of the American Tax Payer Relief Act on stereotactic radiosurgery utilization in the United States

Shearwood McClelland, Catherine Degnin, Yiyi Chen, Gordon A. Watson, Jerry Jaboin

Research output: Contribution to journalArticle

Abstract

Introduction: Single-fraction stereotactic radiosurgery (SRS) is delivered predominantly via two modalities: Gamma Knife, and linear accelerator (LINAC). Implementation of the American Tax Payer Relief Act (ATRA) in 2013 represented the first time limitations specifically targeting SRS reimbursement were introduced into federal law. The subsequent impact of the ATRA on SRS utilization in the United States (US) has yet to be examined. Methods: The National Cancer Database from 2010–2016 identified brain metastases patients from non-small cell lung cancer throughout the US having undergone SRS. Utilization between GKRS and LINAC was assessed before (2010–2012), during (2013–2014) and after (2015–2016) ATRA implementation. Results: In 2013, there was a substantial decrease of LINAC SRS in favor of GKRS in non-academic centers. Over the 3-year span immediately preceding ATRA implementation, 39% of all eligible SRS cases received LINAC. There was a modest decrease in LINAC utilization over the 2 years immediately following ATRA implementation (35%), followed by an increase over the next two years (40%). SRS modality showed differences over the three time periods (unadjusted, p = 0.043), primarily in non-academic centers (unadjusted, p = 0.003). Conclusions: ATRA implementation in 2013 caused an initial spike in Gamma Knife SRS utilization, followed by a decline to rates similar to the years before implementation. These findings indicate that the ATRA provision mandating Medicare reduction of outpatient payment rates for Gamma Knife to be equivalent with those of LINAC SRS had a significant short-term impact on the radiosurgical treatment of metastatic brain disease throughout the US, serving as a reminder of the importance/impact of public policy on treatment modality utilization by physicians and hospitals.

Original languageEnglish (US)
JournalJournal of Neuro-Oncology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Radiosurgery
Taxes
Particle Accelerators
Brain Diseases
Public Policy
Medicare
Non-Small Cell Lung Carcinoma
Outpatients
Databases

Keywords

  • American Tax Payer Relief Act
  • Brain metastases
  • Gamma knife
  • Linear accelerator
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Impact of the American Tax Payer Relief Act on stereotactic radiosurgery utilization in the United States. / McClelland, Shearwood; Degnin, Catherine; Chen, Yiyi; Watson, Gordon A.; Jaboin, Jerry.

In: Journal of Neuro-Oncology, 01.01.2019.

Research output: Contribution to journalArticle

@article{b18377f7215848628800876f22866195,
title = "Impact of the American Tax Payer Relief Act on stereotactic radiosurgery utilization in the United States",
abstract = "Introduction: Single-fraction stereotactic radiosurgery (SRS) is delivered predominantly via two modalities: Gamma Knife, and linear accelerator (LINAC). Implementation of the American Tax Payer Relief Act (ATRA) in 2013 represented the first time limitations specifically targeting SRS reimbursement were introduced into federal law. The subsequent impact of the ATRA on SRS utilization in the United States (US) has yet to be examined. Methods: The National Cancer Database from 2010–2016 identified brain metastases patients from non-small cell lung cancer throughout the US having undergone SRS. Utilization between GKRS and LINAC was assessed before (2010–2012), during (2013–2014) and after (2015–2016) ATRA implementation. Results: In 2013, there was a substantial decrease of LINAC SRS in favor of GKRS in non-academic centers. Over the 3-year span immediately preceding ATRA implementation, 39{\%} of all eligible SRS cases received LINAC. There was a modest decrease in LINAC utilization over the 2 years immediately following ATRA implementation (35{\%}), followed by an increase over the next two years (40{\%}). SRS modality showed differences over the three time periods (unadjusted, p = 0.043), primarily in non-academic centers (unadjusted, p = 0.003). Conclusions: ATRA implementation in 2013 caused an initial spike in Gamma Knife SRS utilization, followed by a decline to rates similar to the years before implementation. These findings indicate that the ATRA provision mandating Medicare reduction of outpatient payment rates for Gamma Knife to be equivalent with those of LINAC SRS had a significant short-term impact on the radiosurgical treatment of metastatic brain disease throughout the US, serving as a reminder of the importance/impact of public policy on treatment modality utilization by physicians and hospitals.",
keywords = "American Tax Payer Relief Act, Brain metastases, Gamma knife, Linear accelerator, Stereotactic radiosurgery",
author = "Shearwood McClelland and Catherine Degnin and Yiyi Chen and Watson, {Gordon A.} and Jerry Jaboin",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s11060-019-03283-z",
language = "English (US)",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Impact of the American Tax Payer Relief Act on stereotactic radiosurgery utilization in the United States

AU - McClelland, Shearwood

AU - Degnin, Catherine

AU - Chen, Yiyi

AU - Watson, Gordon A.

AU - Jaboin, Jerry

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Single-fraction stereotactic radiosurgery (SRS) is delivered predominantly via two modalities: Gamma Knife, and linear accelerator (LINAC). Implementation of the American Tax Payer Relief Act (ATRA) in 2013 represented the first time limitations specifically targeting SRS reimbursement were introduced into federal law. The subsequent impact of the ATRA on SRS utilization in the United States (US) has yet to be examined. Methods: The National Cancer Database from 2010–2016 identified brain metastases patients from non-small cell lung cancer throughout the US having undergone SRS. Utilization between GKRS and LINAC was assessed before (2010–2012), during (2013–2014) and after (2015–2016) ATRA implementation. Results: In 2013, there was a substantial decrease of LINAC SRS in favor of GKRS in non-academic centers. Over the 3-year span immediately preceding ATRA implementation, 39% of all eligible SRS cases received LINAC. There was a modest decrease in LINAC utilization over the 2 years immediately following ATRA implementation (35%), followed by an increase over the next two years (40%). SRS modality showed differences over the three time periods (unadjusted, p = 0.043), primarily in non-academic centers (unadjusted, p = 0.003). Conclusions: ATRA implementation in 2013 caused an initial spike in Gamma Knife SRS utilization, followed by a decline to rates similar to the years before implementation. These findings indicate that the ATRA provision mandating Medicare reduction of outpatient payment rates for Gamma Knife to be equivalent with those of LINAC SRS had a significant short-term impact on the radiosurgical treatment of metastatic brain disease throughout the US, serving as a reminder of the importance/impact of public policy on treatment modality utilization by physicians and hospitals.

AB - Introduction: Single-fraction stereotactic radiosurgery (SRS) is delivered predominantly via two modalities: Gamma Knife, and linear accelerator (LINAC). Implementation of the American Tax Payer Relief Act (ATRA) in 2013 represented the first time limitations specifically targeting SRS reimbursement were introduced into federal law. The subsequent impact of the ATRA on SRS utilization in the United States (US) has yet to be examined. Methods: The National Cancer Database from 2010–2016 identified brain metastases patients from non-small cell lung cancer throughout the US having undergone SRS. Utilization between GKRS and LINAC was assessed before (2010–2012), during (2013–2014) and after (2015–2016) ATRA implementation. Results: In 2013, there was a substantial decrease of LINAC SRS in favor of GKRS in non-academic centers. Over the 3-year span immediately preceding ATRA implementation, 39% of all eligible SRS cases received LINAC. There was a modest decrease in LINAC utilization over the 2 years immediately following ATRA implementation (35%), followed by an increase over the next two years (40%). SRS modality showed differences over the three time periods (unadjusted, p = 0.043), primarily in non-academic centers (unadjusted, p = 0.003). Conclusions: ATRA implementation in 2013 caused an initial spike in Gamma Knife SRS utilization, followed by a decline to rates similar to the years before implementation. These findings indicate that the ATRA provision mandating Medicare reduction of outpatient payment rates for Gamma Knife to be equivalent with those of LINAC SRS had a significant short-term impact on the radiosurgical treatment of metastatic brain disease throughout the US, serving as a reminder of the importance/impact of public policy on treatment modality utilization by physicians and hospitals.

KW - American Tax Payer Relief Act

KW - Brain metastases

KW - Gamma knife

KW - Linear accelerator

KW - Stereotactic radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=85072223654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072223654&partnerID=8YFLogxK

U2 - 10.1007/s11060-019-03283-z

DO - 10.1007/s11060-019-03283-z

M3 - Article

C2 - 31485922

AN - SCOPUS:85072223654

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

ER -